# A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis

> **NCT04152226** · PHASE2 · COMPLETED · sponsor: **DermBiont, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** Janthinobacterium lividum

## Key facts

- **NCT ID:** NCT04152226
- **Lead sponsor:** DermBiont, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-19
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152226, "A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04152226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*